PRIME – Prostate Cancer: Regional Insights and Multidisciplinary Excellence
PRIME – Prostate Cancer: Regional Insights and Multidisciplinary Excellence
Speakers: Michael Chang, Kim Chi & Michael Ong
Objectives
By participating in this learning program, healthcare providers will be able to:
- Understand the latest testing and treatment considerations for advanced prostate cancer (PCa) patients with genetic mutations, including those with HRR and MMR mutations.
- Navigate complex advanced PCa cases across diverse healthcare settings.
- Leverage multi-disciplinary insights on effective adverse event management.
- Employ strategies to optimize multidisciplinary patient care plans.
ACCREDITATION
This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 2 hours of credit.
This program has received financial support from AstraZeneca/Merck Alliance in the form of an educational grant.